By modulating the brains dopamine reward system, GLP-1 agonists show promise in reducing cravings and compulsive behaviors associated with various substance use disorders, including alcohol, nicotine, and potentially opioids and stimulants [14, 16, 17]
However, it is important to consider our study period and the recent launch of the 3.0 mg and 4.5 mg dosage formulations in France in July 2021, as well as the coronavirus disease (COVID-19) pandemic, which decreased access to primary care access and may have potentially lessened the likelihood of initiating new dosage formulations in patients [16, 17]
Does PlexusDx semaglutide work the same as Ozempic
Possibly, but the choice depends on diagnosis, eligibility, response, side effects, contraindications, other medicines, and insurance coverage
Teskey G, Abraham R, Cao R, Gyurjian K, Islamoglu H, Lucero M, Martinez A, Paredes E, Salaiz O, Robinson B, Venketaraman V